In the latter case, primary, donor-derived NK cells were genetically modified to express a CAR targeting the C-type lectin-like molecule-1 (CLL-1/ C-Type Lectin Domain Family 12 Member A, CLEC12A) against acute myeloid leukemia (AML) cell lines and primary AML blasts. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.